The findings were presented in a late-breaking presentation, “MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer,” at the European Society for Medical Oncology (ESMO) 2019 Congress, held Sept. 27–Oct. 1 in Barcelona, Spain, and published simultaneously in JAMA Oncology.
Verzenio is a cancer medication marketed by Eli Lilly. It is a strong inhibitor of cyclin-dependent kinases (CDK)4/6, which are enzymes that regulate cell proliferation and growth, and often are overactive in breast cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of certain types of advanced or metastatic breast cancers.